Lurasidone in Post-menopausal Females With Major Depressive Disorder With Mixed Features–Post-hoc Analysis of a Placebo-Controlled Trial

Several studies have found that depressed, post-menopausal females may respond differently to
antidepressants compared to pre-menopausal females. The atypical antipsychotic lurasidone, whose mechanism of action differs from SSRIs and other standard antidepressants, was shown in a 6-week randomized, flexibledose, placebo-controlled study (n = 209), to be effective in treating major depressive disorder (MDD) with mixed features (subthreshold hypomanic symptoms). This post-hoc analysis assessed the efficacy of lurasidone in this study by menopausal status.